- Parties: The plaintiffs were Genevant Sciences Corporation and Genevant Sciences GmbH. The defendants were Moderna Biopharma Canada Corporation, Moderna Inc, and Modernatx Inc.

- Subject Matter: This Federal Court patent infringement action involves claims by Genevant Sciences GmbH and Genevant Sciences Corporation that Moderna Biopharma Canada Corporation, Moderna, Inc., and ModernaTX, Inc. infringed the "333 Patent" relating to lipid nanoparticle (LNP) delivery technology, which Genevant alleges is used in Moderna's COVID-19 vaccine (the "Moderna Product"). The Reply, filed June 10, 2025, responds to Moderna's Fresh as Amended Statement of Defence by denying all invalidity allegations, asserting that the 333 Patent is valid and infringed, and contesting Moderna's defences including lack of standing, anticipation, obviousness, double patenting, inutility, insufficiency, overbreadth, and ambiguity. The case is ongoing.

- Date: The hearing was set on March 05, 2026.

- Venue: This was a federal case before the Federal Court in Toronto.

- Amount: No financial award was specified.